Liberty Leaf Announces the Appointment of Dr. Robert Jackman as Scientific Project Manager
Vancouver, B.C. – February 1, 2018: Liberty Leaf President & CEO, Will Rascan, announced today the appointment of Dr. Robert Jackman as Scientific Project Manager/Fulfillment. Liberty Leaf Holdings Ltd. (CSE: LIB, OTCQB: LIBFF and FSE: HN3P) (“Liberty Leaf”) is a Canadian-based, public company whose objective is to be at the forefront of the cannabis industry, accelerating revenue-generating businesses within this rapidly growing sector.
“We are very pleased to welcome Dr. Jackman,” said Will Rascan, President and CEO of Liberty Leaf Holdings, Ltd. “He brings a wealth of scientific experience and expertise to the team that will prove invaluable over the coming months and years.”
Dr. Jackman has enjoyed an extensive career as a consultant in research and development, following an illustrious track record in Academia. He has shepherded a number of new products through the vetting process, helping to bring innovative patents to market successfully.
Furthermore, Dr. Jackman has worked closely with multiple clients in the Medical Cannabis and Natural and Non-prescription Health Products (NNHP) Industries in North America to facilitate, prepare and submit Licensed Producer, NNHP and site licenses.
Among wide-ranging responsibilities, Dr. Jackman will be spearheading a variety of activities for Liberty Leaf, North Road Ventures, Just Kush and other Liberty Leaf enterprises, including identifying and assessing science-based projects.
“I am delighted to be part of the Liberty Leaf success story as it unfolds,” Dr. Jackman said. “I consider this to be a great honour and opportunity.”
Over 25 Peer-Reviewed Journal Articles, 6 Book Chapters, 2 Patents, and Several Records of Invention
Dr. Jackman is a Food Scientist, with an undergraduate degree (BSc, Hon) from the University of British Columbia, as well as graduate degrees (MSc, PhD) from the University of Guelph.
Since 2002, Dr. Jackman has been providing R&D and technical support services to the Food, NNHP and Medical Cannabis industries:
- Advising corporate clients on regulatory and GMP compliance matters
- Preparing and implementing Standard Operating Procedures and policies
- Troubleshooting process and product non-conformances and off-specifications
- Recommending corrective and preventive actions and process and product improvements
- Preparing site and product license applications, and industry SR&ED tax claim reports
- Analyzing and interpreting analytical and technical data
- And recommending tests, methods and/or processes to ensure product quality and compliance
Dr. Jackman has been successful in obtaining over 60 NNHP Licenses, most for difficult to license combination products, and several NNHP site licenses, on behalf of multiple and diverse clients.
“The vertically-integrated business interests of Liberty Leaf provide almost limitless growth potential,” said Dr. Jackman. “I am confident in being able to help sustain this growth potential by leading special projects and providing sound scientific guidance and expertise.”
About Liberty Leaf
Liberty Leaf Holdings Ltd. is a Canadian-based, public company whose focus is to build and support a diversified portfolio of cannabis-sector businesses, including cultivation, processing, value-added CBD/THC pet products and supply-chain products within this dynamic and fast-growing sector. Liberty Leaf’s late-stage ACMPR portfolio consists of a 60% interest in Just Kush and 100% of North Road Ventures. For further info on the Company please visit http://www.libleaf.com or email firstname.lastname@example.org.
On behalf of the Board
Will Rascan, President & CEO
Liberty Leaf Holdings Ltd.
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The Company disclaims any intention or obligation to revise or update such statements.